Report
ASH 2022. Pre-Conference Synopsis on CAR-T & TCE Space
This pre-conference synopsis for ASH 2022 highlights key developments in the CAR-T and T-cell engager (TCE) therapy landscape for hematologic malignancies. The conference featured more than 5,200 abstracts, including over 280 focused on CAR-T therapies and more than 40 on T-cell engagers, reflecting strong momentum in cellular immunotherapy research. Lymphoma was the dominant therapeutic area, accounting for approximately 42% of CAR-T and TCE-related sessions, followed by leukemia at 27% and myeloma at 22%. Multiple scientific programs, workshops, symposia, and poster presentations showcased advances across indications such as multiple myeloma, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and acute myeloid leukemia. The report underscores the growing clinical and research f
